ArticleFrontiers in pharmacology2026
Fuzheng Huayu tablets reduces the risk of further decompensation after the first decompensation in patients with HBV-related cirrhosis: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07017426 (Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The first decompensation event of cirrhosis is a critical point of disease progression, and the incidence of further decompensation occurs up to more than 50%. Fuzheng Huayu tablet is used as a classic anti-hepatic fibrosis herbal compound. There is no randomized controlled trial (RCT) combining Fuzheng Huayu tablet with antiviral to prevent the occurrence of further decompensation. The aim of this study was to conduct a prospective randomized, double-blind, placebo-controlled, multicenter study to investigate its safety and efficacy in terms of the risk of further decompensation events in patients with first decompensation, and to fill the gap of evidence-based medicine in this field. Methods and analysis: This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1. Participants will be randomly assigned to the two groups using a stratified block randomization method at the central level. The Fuzheng Huayu group (Fuzheng Huayu tablets combined with conventional antiviral therapy) and the placebo group (placebo combined with conventional antiviral therapy) will be treated for 48 weeks and followed up to 96 weeks. The study period will last for a total of 2 years. The cumulative incidence of further decompensation events within 1-year, the cumulative incidence of recompensation within 1-year, the incidence of liver failure, hepatocellular carcinoma, and liver disease-related deaths will be analyzed. Discussion: This study will be a prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the clinical benefit of Fuzheng Huayu tablets in the risk of further decompensation events in patients with first decompensation. Clinical Trial Registration: Clinical Trials.gov, study ID NCT07017426; International Traditional Medicine Clinical Trial Registry, registration number ITMCTR2025001365.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.